Reirradiation of prostate cancer with rectum preservation: Eradicative high-dose-rate brachytherapy with natural type hyaluronate injection

Brachytherapy

Volumn 11, Issue 2, 2012, Pages 144-148

  Kishi, Kazushi ^a,b   Sato, Morio ^b   Shirai, Shintaro ^b   Sonomura, Tetsuo ^b   Yamama, Ryuichi ^c  

^a WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c Kishiwada Tokushukai Hospital   (Japan)

Author keywords

D2 cc; High dose rate brachytherapy; Hyaluronic acid; Prostate cancer; Rectum; Reirradiation; Risk organ

Indexed keywords

HYALURONIC ACID;

AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CASE REPORT; DRUG MEGADOSE; FOLLOW UP; GEL; HOSPITAL; HUMAN; IRRADIATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM;

ADJUVANTS, IMMUNOLOGIC; AGED; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; HYALURONIC ACID; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTAL DISEASES; RECTUM;

EID: 84857800896     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.06.006     Document Type: Article

References (37)

1. Stone N., Potters L., Davis B., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:341-346.
2. Kuban D., Pollack A., Huang E., et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1260-1268.
3. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
4. Dahl E., Polacek M., Hagen T.S., et al. Tidsskr Nor Laegeforen 2007, 127:1032-1035. [Norwegian].
5. Egawa S., Shimura S., Irie A., et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001, 31:541-547.
6. Anastasiadis A.G., Sachdev R., Salomon L., et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol 2003, 129:676-682.
7. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
8. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54:880-883.
9. Vavassori A., Jereczek-Fossa B.A., Beltramo G., et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: Retrospective feasibility study on six cases. Tumori 2010, 96:71-75.
10. Huang E., Pollack A., Levy L., et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002, 54:1314-1321.
11. Zelefsky M., Levin E., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
12. Jackson A. Partial irradiation of the rectum. Semin Radiat Oncol 2001, 11:215-223.
13. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001, 49:685-698.
14. Rancati T., Fiorino C., Gagliardi G., et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004, 73:21-32.
15. Kishi K, Adati H, Takada K. Implants for radiation therapy. In: Office JP, editor. Patent publication bulletin. No. 106149. Tokyo, Japan: Japan Patent Office; 2004.
16. Kishi K., Takifuji K., Shirai S., et al. Brachytherapy technique for abdominal wall metastases of colorectal cancer: Ultrasound-guided insertion of applicator needle and a skin preservation method. Acta Radiol 2006, 47:157-161.
17. Kishi K, Shirai S, Sato M, et al. Preservation of risk organs in critical brachytherapy by tissue spacing with percutaneous injection. The 5th Japan-US Cancer Therapy Symposium & The 5th S Takahashi Memorial Joint Symposium. Sendai, Japan: The 5th Japan-US Cancer Therapy Symposium & The 5th S. Takahashi Memorial Joint Symposium Committee; 2007: p. 10023 (No. of presentation).
18. Kishi K., Shirai S., Sato M., et al. Computer-aided preservation of risk organs in critical brachytherapy by tissue saving with percutaneous injection of hyaluronic acid solution. Int J Radiat Oncol Biol Phys 2007, 69:S568-S569.
19. Kishi K., Sonomura T., Shirai S., et al. Critical organ preservation in reirradiation brachytherapy by injectable spacer. Int J Radiat Oncol Biol Phys 2009, 75:587-594.
20. Vordermark D., Guckenberger M., Baier K., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: In regard to Prada, et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.). Int J Radiat Oncol Biol Phys 2008, 71:316-317.
21. Prada P.J., Fernandez J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
22. Prada P.J., Gonzalez H., Menendez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
23. Sato M., Mori T., Shirai S., et al. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:1002-1009.
24. Lindsey I., Guy R.J., Warren B.F., et al. Anatomy of Denonvilliers' fascia and pelvic nerves, impotence, and implications for the colorectal surgeon. Br J Surg 2000, 87:1288-1299.
25. Campo G., Avenoso A., Campo S., et al. The antioxidant effect exerted by TGF-1beta-stimulated hyaluronan production reduced NF-kB activation and apoptosis in human fibroblasts exposed to FeSo4 plus ascorbate. Mol Cell Biochem 2008, 311:167-177.
26. Krasinski R., Tchorzewski H., Lewkowicz P. Antioxidant effect of hyaluronan on polymorphonuclear leukocyte-derived reactive oxygen species is dependent on its molecular weight and concentration and mainly involves the extracellular space. Postepy Hig Med Dosw (Online) 2009, 63:205-212.
27. Restylane® International Restylane Available at:, Accessed December 1, 2010. http://www.restylane.com.
28. Hamilton R., Strobos J., Adkinson N. Immunogenicity studies of cosmetically administered nonanimal-stabilized hyaluronic acid particles. Dermatol Surg 2007, 33:s176-s185.
29. Arron S.T., Neuhaus I.M. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol 2007, 6:167-171.
30. Ghislanzoni M., Bianchi F., Barbareschi M., et al. Cutaneous granulomatous reaction to injectable hyaluronic acid gel. Br J Dermatol 2006, 154:755-758.
31. Wolfram D., Tzankov A., Piza-Katzer H. Surgery for foreign body reactions due to injectable fillers. Dermatology 2006, 213:300-304.
32. Wiest L.G., Stolz W., Schroeder J.A. Electron microscopic documentation of late changes in permanent fillers and clinical management of granulomas in affected patients. Dermatol Surg 2009, 35(Suppl 2):1681-1688.
33. Edwards P.C., Fantasia J.E. Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers. Clin Interv Aging 2007, 2:509-519.
34. Christensen L.H. Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers. Dermatol Surg 2009, 35(Suppl 2):1612-1619.
35. Thomas C., Keyes M., Liu M., et al. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 72:447-455.
36. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000, 46:391-402.
37. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005, 62:981-987.